US20100016448A1 - Flashmelt oral dosage formulation - Google Patents

Flashmelt oral dosage formulation Download PDF

Info

Publication number
US20100016448A1
US20100016448A1 US12/558,813 US55881309A US2010016448A1 US 20100016448 A1 US20100016448 A1 US 20100016448A1 US 55881309 A US55881309 A US 55881309A US 2010016448 A1 US2010016448 A1 US 2010016448A1
Authority
US
United States
Prior art keywords
casio
pharmaceutical product
crystalline
axial diameter
aripiprazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/558,813
Other languages
English (en)
Inventor
Sanjeev Kothari
Divyakant S. Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24186805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100016448(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/973,226 external-priority patent/US20020076437A1/en
Priority claimed from US10/920,851 external-priority patent/US20050019398A1/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to US12/558,813 priority Critical patent/US20100016448A1/en
Publication of US20100016448A1 publication Critical patent/US20100016448A1/en
Priority to US13/108,193 priority patent/US8518421B2/en
Priority to US13/938,706 priority patent/US9358207B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a formulation for solid pharmaceutical oral dosage forms that rapidly disperses in the mouth.
  • flash-melt dosage forms are intended to dissolve or disintegrate in the mouth of the patient in less than one minute whereas the latter are intended for primary dissolution or disintegration within 3 to 20 minutes in the acidic medium of the stomach or a container of water.
  • the recognized test for rapidly disintegrating dosage forms is disintegration time in 0.1 N hydrochloric acid.
  • dosage form formulations intended for flash-melt or rapid disintegration Another consideration common to most if not all dosage form formulations intended for flash-melt or rapid disintegration is the need to take precautions in the preparation, packaging, handling and storing of the finished dosage forms since they tend to be both hygroscopic and friable. Dosage forms dependent on effervescence to promote their disintegration are particularly susceptible to moisture and must be packaged with special wrapping, stoppers, packets of drying agent and the like.
  • flash-melt dosage forms are advantageous for administration of medicaments to patients such as the very young, the elderly, the non-compliant and those with a physical impairment that makes it difficult if not impossible to swallow an intact dosage form. Flash-melt dosage forms are further a convenience for situations where potable water may not be readily available or desirable. Medicaments amenable to such dosage forms would include sedatives, hypnotics, antipsychotics, motion sickness medication, mild stimulants such as caffeine and the like.
  • the first of these, particularly suited for the preparation of flash-melt dosage forms is freeze drying wherein a cake or wafer is prepared from a freeze-dried solution or suspension of medicament and suitable excipients in water or other solvents. Such wafers dissolve very rapidly on the tongue, i.e. within about ten seconds, due to a combination of a high affinity for moisture resulting from the freeze drying process and a very high porosity, which promotes rapid ingress of saliva.
  • the second major technology utilized in the manufacture of rapidly disintegrating dosage forms is based on special grades of sugars such as mannitol, sorbitol and the like in combination with superdisintegrants.
  • the latter are excipients that are characterized by a special wicking capacity to channel water into the interior of the dosage form, or by rapid swelling in water, both of which act to hasten disintegration.
  • effervescent combinations typically sodium bicarbonate and a weak acid, such as citric acid.
  • effervescent formulations require special moisture resistant packaging as even very small levels of moisture may be sufficient to initiate the effervescent reaction.
  • WO 98/030640 An example of a teaching of the incorporation of super disintegrants in dosage form formulations to enhance dissolution is WO 98/030640, FMC Corporation. It is disclosed therein that, for cost considerations, up to 90% of a group of super disintegrants including cross-linked cellulose, cross-linked carboxymethyl cellulose, cross-linked starch, croscarmellose alkali metal salt, crospovidone, alkali metal starch glycolate and the like can be replaced by a co-disintegrant. Included among the latter group are natural diatomaceous silica, a synthetic hydrous alkaline earth metal calcium silicate and a porous hydrophilic zeolite.
  • the weight ratio of super disintegrant to co-disintegrant is stated as from 4:1 to 1:10, preferably 2-1:1.
  • Japanese patent 10114655 Kyowa Hakko Kogyo KK discloses a formulation intended for rapid dissolution in the stomach that can contain up to 30% by weight of a superdisintegrant, such as crospovidone or hydroxypropylcellulose, croscarmellose and the like and up to 30% of a neutral or basic ingredient including magnesium aluminum metasilicate, calcium silicate, a phosphoric acid salt or a metal hydroxide.
  • the dosage form is intended for medicaments that produce a gel at acidic pH.
  • a flash-melt pharmaceutical dosage form comprising a medicament, a superdisintegrant, a dispersing agent and a binder wherein said medicament is aripiprazole, entecavir, cefprozil, pravastatin, captopril, gatifloxacin, desquinolone, omapatrilat or irbesartan and wherein said dispersing agent is calcium silicate, magnesium trisilicate or silicic acid.
  • flash-melt pharmaceutical dosage forms as described herein wherein greater than 50% of said dispersing agent by weight is comprised of calcium silicate.
  • flash-melt pharmaceutical dosage forms as described herein wherein greater than 80% of said dispersing agent by weight is comprised of calcium silicate.
  • flash-melt pharmaceutical dosage forms as described herein wherein said dispersing agent is calcium silicate.
  • flash-melt pharmaceutical dosage forms as described herein wherein said dispersing agent comprises from about 20 to about 70 percent by weight of said dispersing agent based on the total weight of said dosage form.
  • flash-melt pharmaceutical dosage forms as described herein wherein said dispersing agent comprises from about 35 to about 45 percent by weight of said dispersing agent based on the total weight of said dosage form.
  • flash-melt pharmaceutical dosage forms as described herein wherein said calcium silicate is crystalline.
  • flash-melt pharmaceutical dosage forms as described herein wherein said calcium silicate is amorphous.
  • flash-melt pharmaceutical dosage forms as described herein wherein said calcium silicate is ortho-, meta- or alpha triclinic-calcium silicate.
  • flash-melt pharmaceutical dosage forms as described herein wherein said calcium silicate is alpha triclinic-calcium silicate.
  • flash-melt pharmaceutical dosage forms as described herein wherein said calcium silicate is comprised of a combination of alpha triclinic-calcium silicate and at least one other pharmaceutical grade of calcium silicate wherein said alpha triclinic-calcium silicate comprises from about 10% to about 90% by weight of said combination.
  • flash-melt pharmaceutical dosage forms as described herein wherein said calcium silicate has a surface area of 1.0 m 2 /gm to 210 m 2 /gm, bulk density of 0.075 g/cc to 0.90 g/cc, true density of 1.70 g/cc to 2.90 g/cc and volatile content of less than 1% to 14% w/w.
  • flash-melt pharmaceutical dosage forms as described herein wherein said calcium silicate is alpha triclinic calcium silicate that has a surface area of about 1.3 m 2 /gm, bulk density of about 0.63 g/cc, true density of about 2.90 g/cc and volatile content of less than 1% w/w.
  • flash-melt pharmaceutical dosage forms as described herein wherein said calcium silicate is ortho crystalline calcium silicate that has a surface area of about 0.98 m 2 /gm, bulk density of about 0.492 g/cc, true density of about 3.252 g/cc and volatile content of less than 1% w/w.
  • flash-melt pharmaceutical dosage forms as described herein wherein said calcium silicate is meta crystalline calcium silicate that has a surface area of about 2.5 m 2 /gm, bulk density of about 0.867 g/cc, true density of about 2.940 g/cc and volatile content of less than 1% w/w.
  • flash-melt pharmaceutical dosage forms as described herein wherein said calcium silicate is crystalline calcium silicate that has a surface area of about 90.4 m 2 /gm, bulk density of about 0.094 g/cc, true density of about 2.596 g/cc and volatile content of less than 1% w/w.
  • flash-melt pharmaceutical dosage forms as described herein wherein said calcium silicate is amorphous calcium silicate that has a surface area of about 191.3 m 2 /gm, bulk density of about 0.120 g/cc, true density of about 2.314 g/cc and volatile content of about less than 14% w/w.
  • flash-melt pharmaceutical dosage forms as described herein wherein said calcium silicate is amorphous calcium silicate that has a surface area of about 103.0 m 2 /gm, bulk density of about 0.130 g/cc, true density of about 1.702 g/cc and volatile content of about less than 14% w/w.
  • flash-melt pharmaceutical dosage forms as described herein wherein said calcium silicate is amorphous calcium silicate that has a surface area of about 209 m 2 /gm, bulk density of about 0.075 g/cc, true density of about 2.035 g/cc and volatile content of about less than 14% w/w.
  • flash-melt pharmaceutical dosage forms as described herein wherein said medicament comprises not more than about 30 percent by weight of said medicament based on the total weight of said dosage form.
  • flash-melt pharmaceutical dosage forms as described herein wherein said medicament comprises not more than about 15 percent by weight of said medicament based on the total weight of said dosage form.
  • flash-melt pharmaceutical dosage forms as described herein wherein said medicament is selected from the group consisting of aripiprazole, entecavir, cefprozil, pravastatin, captopril, gatifloxacin, desquinolone, omapatrilat and irbesartan.
  • flash-melt pharmaceutical dosage forms as described herein wherein said medicament is aripiprazole.
  • flash-melt pharmaceutical dosage forms as described herein wherein said superdisintegrant agent comprises from about 3 to about 15 percent by weight of said superdisintegrant agent based on the total weight of said dosage form.
  • flash-melt pharmaceutical dosage forms as described herein wherein said superdisintegrant agent comprises from about 4 to about 10 percent by weight of said superdisintegrant agent based on the total weight of said dosage form.
  • flash-melt pharmaceutical dosage forms as described herein wherein said superdisintegrant agent comprises from about 4 to about 8 percent by weight of said superdisintegrant agent based on the total weight of said dosage form.
  • flash-melt pharmaceutical dosage forms as described herein wherein said superdisintegrant agent comprises from about 5 to about 7 percent by weight of said superdisintegrant agent based on the total weight of said dosage form.
  • flash-melt pharmaceutical dosage forms as described herein wherein said superdisintegrant agent comprises from about 8 to about 12 percent by weight of said superdisintegrant agent based on the total weight of said dosage form.
  • flash-melt pharmaceutical dosage forms as described herein wherein said superdisintegrant agent comprises from about 9 to about 10 percent by weight of said superdisintegrant agent based on the total weight of said dosage form.
  • flash-melt pharmaceutical dosage forms as described herein wherein said superdisintegrant agent is crospovidone, croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropyl cellulose or pregelatinized starch.
  • flash-melt pharmaceutical dosage forms as described herein wherein said superdisintegrant agent is crospovidone or croscarmellose sodium.
  • flash-melt pharmaceutical dosage forms as described herein wherein said superdisintegrant agent is crospovidone and croscarmellose sodium.
  • flash-melt pharmaceutical dosage forms as described herein, wherein based on the total weight of said dosage form, said crospovidone comprises from about 6 to about 8 percent by weight of said crospovidone and said croscarmellose sodium comprises from about 2 to about 4 percent by weight of said croscarmellose sodium.
  • flash-melt pharmaceutical dosage forms as described herein wherein said distributing agent comprises from about 1 to about 10 percent by weight of said distributing agent based on the total weight of said dosage form.
  • flash-melt pharmaceutical dosage forms as described herein wherein said distributing agent comprises from about 1.5 to about 3 percent by weight of said distributing agent based on the total weight of said dosage form.
  • flash-melt pharmaceutical dosage forms as described herein wherein said distributing agent is amorphous silica, fumed silica, diatomaceous earth, talc, kaolin or magnesium aluminum trisilicate.
  • flash-melt pharmaceutical dosage forms as described herein wherein said distributing agent comprises from about 10 to about 50 percent by weight of said binder based on the total weight of said dosage form.
  • flash-melt pharmaceutical dosage forms as described herein wherein said distributing agent comprises from about 12 to about 20 percent by weight of said binder based on the total weight of said dosage form.
  • flash-melt pharmaceutical dosage forms as described herein wherein said binder is microcrystalline cellulose, hydroxypropyl cellulose, ethyl cellulose, lactose, mannitol or calcium phosphate.
  • a medicament means that one or more of agents belonging to each class may be suitably employed in the present invention unless otherwise specified.
  • agents belonging to a particular class are referred to in the alternative, it is understood that one or more of said agents may be suitably employed.
  • two or more superdisintegrants may be employed unless otherwise specified.
  • the flash-melt pharmaceutical dosage forms the present invention may be prepared by dry granulation of the excipients with the medicament and suitable conventional ingredients, such as flavoring and sweetening agents, without the use of any solvent, to form stable granules that can be readily compressed into dosage forms on conventional equipment without the need for special handling techniques.
  • the active medicament may comprise up to about 30% by weight, particularly up to about 15% by weight, of the formulation, depending on the amount required for a therapeutically effective dosage and factors such as its capacity to be directly granulated, the amount of flavoring/sweetening agents required to mask the taste or bitterness thereof and the like. It is within the scope of the present invention to utilize medicaments that are coated for taste or other reason in the subject formulations provided that the coatings do not interfere with either the compounding or the disintegration of the tablets.
  • Suitable superdisintegrants include crospovidone, croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropylcellulose, pregelatinized starch and the like. Crospovidone can be utilized in large amounts without causing a formulation containing it to have a propensity to gel.
  • Suitable dispersing agents include calcium silicate-ortho, meta and alpha triclinic forms thereof, magnesium trisilicate-ortho and meta forms thereof and silicic acid.
  • Calcium silicate is the preferred dispersing agent.
  • Particularly preferred is a crystalline alpha triclinic calcium silicate, commercially available from Aldrich Chemical Company which meets the following specifications: 1.3 m 2 /gm surface area; 0.63 g/cc bulk density; 2.90 g/cc true density; and ⁇ 1% w/w volatiles.
  • a crystalline alpha triclinic calcium silicate commercially available from J.M.
  • Huber Inc. Tomita Pharmaceutical Co., Aldrich Chemical Company which meets the following specifications: 1.0 to 15 m 2 /gm surface area; 0.50 to 0.63 g/cc bulk density; 2.40 to 2.90 g/cc true density; and ⁇ 1% w/w volatiles.
  • Alpha triclinic calcium silicate is advantageously combined in the subject formulations with at least one other pharmaceutical grade of calcium silicate wherein the alpha triclinic form would comprise from about 10% to about 90% by weight of the combination.
  • the dispersing agent i.e. calcium silicate
  • the primary constituent of the excipient combination of the subject formulations since it is generally recognized by those of ordinary skill in the art as being poorly compressible.
  • Suitable distributing agents for the excipient combination of the subject formulations include amorphous silica, fumed silica, diatomaceous earth, talc, kaolin, magnesium aluminum trisilicate and the like.
  • Suitable binders are those that also function as a wicking or distributing agent in that they act to promote water intake into dosage forms made therefrom.
  • Suitable binders include carbohydrates such as, microcrystalline cellulose, hydroxypropyl cellulose, ethyl cellulose, starch, lactose, and also, mannitol and calcium phosphate.
  • Microcrystalline cellulose is commercially available as Avicel® PH (pharmaceutical grade) from FMC Corporation, Philadelphia, Pa., particularly Avicel® PH 101, PH 102, PH 103, PH 112, PH 200, PH 301, PH 302 and Ceolus.
  • Microcrystalline cellulose is also available from Mendell, Penwest Company, Patterson, N.Y., as Emcocel® 90M and Emcocel® 50M, which could be used satisfactorily.
  • the formulations of the present invention may contain other conventional ingredients found in similar preparations known in the art and recognized as approved for use in preparations to be taken into the body. These would include, for example, natural and artificial flavors, polyols such as mannitol, sorbitol, maltitol and xylitol, artificial sweetening agents such as, N- ⁇ -L-Aspartyl-L-phenylalanine 1-methyl ester (aspartame) and 6-methyl-3,4-dihydro-1,2,3-oxathiazin-4(3H)-one-2,2-dioxide, particularly the potassium salt thereof (acesulfame K), flavor adjuncts such as tartaric acid, tabletting lubricants, such as magnesium stearate, and the like.
  • natural and artificial flavors polyols such as mannitol, sorbitol, maltitol and xylitol
  • artificial sweetening agents such as, N- ⁇ -L-Aspartyl-
  • the amount of flavoring and sweetening agents, if any, present in the formulations of the present invention will be directly proportional to the taste or bitterness of the medicament.
  • the flavoring and sweetening agents do not serve to coat the medicament, but are adequate to mask the objectionable taste of the medicaments in homogeneous admixture therewith.
  • the total of such conventional ingredients will not exceed about 32 percent, preferably from about 25 to about 30 percent by weight based on the total weight of the formulation.
  • the medicament in the formulations of the present invention typically will not exceed about 30 percent by weight, preferably from about 1 to about 15 percent by weight of the formulation.
  • Those of ordinary skill in the art will appreciate that the physical characteristics of the medicament itself, i.e. its particle size and morphology, will directly influence its limiting content in the subject formulations.
  • solid dosage forms can be prepared from the formulations of the present invention by any recognized technique, including wet granulation, it is a particular advantage that the formulations can be dry granulated without the use of specialized equipment and conditions, thereby making them suitable for the formulation of medicaments that are sensitive to moisture and high temperatures.
  • Specific therapeutic agents falling into the foregoing categories include, again without intended limitation, aripiprazole, ibuprofen, aspirin, acetaminophen, chlorpheniramine maleate, psuedoephedrine, diphenhydramine HCl, ranitidine, phenylpropanolamine, cimetidine, loperamide, meclizine, caffeine, entecavir, cefprozil, melatonergic agonists, pravastatin, captopril, fosinopril, irbesartan, omapatrilat, gatifloxacin and desquinolone and therapeutically appropriate combinations thereof.
  • a decided advantage of the formulation of the present invention is that it can be dry-granulated into stable, fine granules that can be directly compressed into pharmaceutically elegant flash-melt oral dosage forms, e.g. tablets, caplets, wafers and the like.
  • the granules for flash-melt dosage forms in accordance with the present invention are formed in two steps.
  • the process comprises initially forming granules, referred to herein as the intragranulation, by blending all of the medicament, the dispersing agent, (distributing agent), other conventional ingredients as described above and a portion of each of the superdisintegrant, binder and tabletting lubricant together in a suitable mixer to assure uniform distribution throughout.
  • a conventional V-blender is a preferred apparatus for this step. While a minor portion of the dispersing agent may be omitted from the intragranulation, it is preferred that all be incorporated therein.
  • the blended mixture is then compacted in a conventional roller compactor having an orifice such that the compacts thereof are in the form of ribbons. Alternately, a slugging process can be used.
  • the compacts from the roller compactor or the slugs from the slugger are passed through a fine screen, e.g. a 30 mesh (600 microns) screen, thereby breaking them into granules between about 150 and 400 microns in size.
  • the intragranulation granules thus-prepared are thereafter blended in a suitable mixer with the remaining ingredients, i.e., superdisintegrant, binder and lubricant, referred to herein as the extragranulation ingredients, to form a final blend that can be directly compressed into pharmaceutical dosage forms utilizing conventional equipment such as a tablet press. Rather than directly compress the final blend upon formation, since it is stable, it can be stored and subsequently pressed into dosage forms at a later time. It is a decided advantage of particular aspects of the subject invention that these operations are carried out without the need to resort to special handling such as taking precautions against any moisture coming in contact with the ingredients or the granules, and without the use of specially controlled temperature and humidity conditions.
  • the intragranulation comprises from about 80 to 99, preferably from about 85 to 95, most preferably about 90, percent by weight of the final blend. Based on the weight of the final blend, the intragranulation preferably comprises up to about 30 percent by weight, preferably from about 6 to 20 percent by weight, of the binder, up to about 5 percent by weight, preferably from about 2 to 4 percent by weight, of the superdisintegrant, and all of the dispersing agent and the distributing agent.
  • the binder and superdisintegrant are divided between the intragranulation and the extragranulation ingredients in weight ratios of approximately 2:1 to 4:1 for the binder and 0.5:2.0 to 2.0:0.5 for the superdisintegrant.
  • the conventional tabletting lubricant is divided approximately equally between the intragranulation and the extragranulation ingredients.
  • the final blend is formed by mixing the intragranulation and the extragranulation components of the excipient combination, adding the remaining tabletting lubricant thereto and blending until uniform.
  • a direct compression approach can be utilized in which all of the ingredients with the exception of the tabletting lubricant are mixed in a suitable blender, such as a conventional V-blender, by geometrically building the entire mass of the formulation via sequential blending for three minutes after each addition, and finally adding the lubricant to the mixture after all other ingredients have been blended.
  • a tablet is considered as disintegrated when it has totally broken down to granules and there are no discernible lumps remaining. Since the medicament is not intimately bound to any of the ingredients of the formulation, it is released within the same time period.
  • Another advantage of particular aspects of the subject formulations is that dosage forms can be manufactured therefrom which are robust and, hence, avoid the need for specialized unit dose packaging and careful handling during manufacture or use as is often the case with present dosage forms.
  • the dosage forms prepared from formulations of particular aspects of the present invention can be packaged in conventional blister packs or in HDPE bottles.
  • Means of manufacturing aripiprazole drug substance for formulating according to the present flashmelt invention may be performed as follows.
  • aripiprazole hydrate (grains) of the present invention have the physicochemical properties given in (1)-(5) below. This aripiprazole hydrate is described hereinafter as “Aripiprazole Hydrate A”.
  • thermogravimetric/differential thermal analysis heating rate 5° C./min
  • endothermic curve which is substantially the same as the thermogravimetric/differential thermal analysis (heating rate 5° C./min) endothermic curve shown in FIG. 1. Specifically, it is characterized by the appearance of a small peak at about 71° C. and a gradual endothermic peak around 60° C. to 120° C.
  • Aripiprazole Hydrate A is manufactured by milling conventional aripiprazole hydrate.
  • the aripiprazole hydrate can be milled in a milling machine.
  • a widely used milling machine can be used, such as an atomizer, pin mill, jet mill or ball mill. Of these, the atomizer is preferred.
  • a rotational speed of 5000-15000 rpm could be used for the main axis, for example, with a feed rotation of 10-30 rpm and a screen hole size of 1-5 mm.
  • the mean grain size of the Aripiprazole Hydrate A obtained by milling should normally be 50 ⁇ m or less, preferably 30 ⁇ m or less. Mean grain size can be ascertained by the grain size measurement method described hereinafter.
  • Grain Size Measurement 0.1 g of the grains to be measured were suspended in a 20 ml n-hexane solution of 0.5 g soy lecithin, and grain size was measured using a size distribution meter (Microtrack HRA, Microtrack Co.).
  • aripiprazole anhydride crystals of the present invention have the physicochemical properties given in (6)-(10) below. These aripiprazole anhydride crystals are referred to hereinafter as “Aripiprazole Anhydride Crystals B”.
  • Aripiprazole Anhydride Crystals B of the present invention have low hygroscopicity.
  • Aripiprazole Anhydride Crystals B of the present invention maintain a water content of 0.4% or less after 24 hours inside a dessicator set at a temperature of 60° C. and a humidity of 100%.
  • Well-known methods of measuring water content can be used as long as they are methods commonly used for measuring the water content of crystals. For example, a method such as the Karl Fischer method can be used.
  • the Aripiprazole Anhydride Crystals B of the present invention are prepared for example by heating the aforementioned Aripiprazole Hydrate A at 90-125° C.
  • the heating time is generally about 3-50 hours, but cannot be stated unconditionally since it differs depending on heating temperature.
  • the heating time and heating temperature are inversely related, so that for example the heating time will be longer the lower the heating temperature, and shorter the higher the heating temperature. Specifically, if the heating temperature of Aripiprazole Hydrate A is 100° C., the heating time should normally be 18 hours or more or preferably about 24 hours. If the heating temperature of Aripiprazole Hydrate A is 120° C., on the other hand, the heating time can be about 3 hours.
  • the Aripiprazole Anhydride Crystals B of the present invention can be prepared with certainty by heating Aripiprazole Hydrate A for about 18 hours at 100° C., and then heating it for about 3 hours at 120° C.
  • the Aripiprazole Anhydride Crystals B of the present invention can also be obtained if the heating time is extended still further, but this is not economical.
  • the Aripiprazole Anhydride Crystals B of the present invention are prepared for example by heating conventional aripiprazole anhydride crystals at 90-125° C.
  • the heating time is generally about 3-50 hours, but cannot be stated unconditionally since it differs depending on heating temperature.
  • the heating time and heating temperature are inversely related, so that for example the heating time will be longer the lower the heating temperature, and shorter the higher the heating temperature. Specifically, if the heating temperature of the aripiprazole anhydride crystals is 100° C., the heating time can be about 4 hours, and if the heating temperature is 120° C. the heating time can be about 3 hours.
  • aripiprazole anhydride crystals which are the raw material for preparing the Aripiprazole Anhydride Crystals B of the present invention are prepared for example by Method a or b below.
  • Aripiprazole anhydride crystals are prepared by well-known methods, as by reacting 7-(4-bromobutoxy)-3,4-dihydrocarbostyril with 1-(2,3-dichlorophenyl)piperadine and recrystallizing the resulting raw aripiprazole crystals with ethanol as described in Example 1 of Japanese Unexamined Patent Publication No. 191256/1990.
  • Aripirazole anhydride crystals are prepared by heating conventional aripiprazole hydrate at a temperature of at least 60° C. and less than 90° C.
  • the heating time is generally about 1-30 hours, but cannot be stated unconditionally since it differs depending on heating temperature.
  • the heating time and heating temperature are inversely related, so that for example the heating time will be longer the lower the heating temperature, and shorter the higher the heating temperature. Specifically, if the heating temperature of the aripiprazole hydrate is about 60° C., the heating time can be about 8 hours, while if the heating temperature is 80° C., the heating time can be about 4 hours.
  • the Aripiprazole Anhydride Crystals B of the present invention are prepared for example by heating conventional aripiprazole hydrate at 90-125° C.
  • the heating time is generally about 3-50 hours, but cannot be stated unconditionally since it differs depending on heating temperature.
  • the heating time and heating temperature are inversely related, so that for example the heating time will be longer the lower the heating temperature, and shorter the higher the heating temperature. Specifically, if the heating temperature of the aripiprazole hydrate is 100° C., the heating time can be about 24 hours, while if the heating temperature is 120° C., the heating time can be about 3 hours.
  • the aripiprazole hydrate which is the raw material for preparing the Aripiprazole Anhydride Crystals B of the present invention is prepared for example by Method c below.
  • Aripiprazole hydrate is easily obtained by dissolving the aripiprazole anhydride crystals obtained by Method a above in a hydrous solvent, and heating and then cooling the resulting solution. Using this method, aripiprazole hydrate is precipitated as crystals in the hydrous solvent.
  • the hydrous solvent should be one which is miscible with water, such as for example an alcohol such as methanol, ethanol, propanol or isopropanol, a ketone such as acetone, an ether such as tetrahydrofuran, dimethylformamide, or a mixture thereof, with ethanol being particularly desirable.
  • the amount of water in the hydrous solvent can be 10-25% by weight of the solvent, or preferably close to 20% by weight.
  • the Aripiprazole Anhydride Crystals B of the present invention are prepared by heating at 90-125° C. of said Aripiprazole Hydrate A, conventional aripiprazole anhydride crystals or conventional aripiprazole hydrate, and said Aripiprazole Hydrate A, conventional aripiprazole anhydride crystals or conventional aripiprazole hydrate may be used either individually or in combination.
  • aripiprazole drug substance made by first milling the conventional hydrate of aripiprazole and then heating it to form the anhydrous form (anhydride B).
  • Flash-melt tablets were prepared as follows:
  • the ingredients except for the magnesium stearate were blended in a commercial V-blender in geometric proportions for 5 minutes each until all were added. The magnesium stearate was then added and the mixture blended for an additional three minutes.
  • the blended formulation was compacted at a pressure of 30-35 kgF/cm 2 in a commercial compactor equipped with an orifice such that the compacts therefrom are in the form of ribbons.
  • the ribbons were passed through a 30 mesh (600 microns) screen to form stable granules of about 150 to 400 microns.
  • the intragranulation was placed in the blender and the Avicel® PH 200 and crospovidone added thereto and blended for five minutes.
  • the magnesium stearate was then added and the mixture blended for an additional three minutes to form the final blend.
  • Tablets compressed therefrom had a breaking force of 2.3 kP (3.5 SCU) and disintegrated in 10 seconds in 5 ml of water.
  • the final blend formulation demonstrated excellent flow and was free of other problems such as chipping, capping and sticking. It has been found that utilizing Avicel® PH 102 for the intragranulation and Avicel® PH 200 for the extragranulation ingredient enhanced the quality of the resultant tablets.
  • Flash-melt tablets containing a combination of two grades of calcium silicate were prepared as follows:
  • the ingredients except for the magnesium stearate were blended in a commercial V-blender in geometric proportions for 5 minutes each until all were added.
  • the magnesium stearate was added and the mixture blended for an additional three minutes.
  • the blended formulation was compacted, and screened to form stable granules in accordance with the procedure of Example 1.
  • the intragranulation was placed in the blender and the Avicel® PH 200 and crospovidone added thereto and blended for five minutes. The magnesium stearate was then added and the mixture blended for an additional three minutes to form the final blend. Tablets compressed therefrom had a breaking force of 2.0 kP (3.1 SCU) and disintegrated in 10 seconds in 5 ml of water.
  • Flash-melt tablets containing aripiprazole, an antischizophrenic drug were prepared as follows:
  • the ingredients except for the magnesium stearate were blended in a commercial V-blender in geometric proportions for 5 minutes each until all were added.
  • the magnesium stearate was added and the mixture blended for an additional three minutes.
  • the blended formulation was compacted, and screened to form stable granules in accordance with the procedure of Example 1.
  • the intragranulation was placed in the blender and the Avicel® PH 200 and crospovidone added thereto and blended for five minutes. The magnesium stearate was then added and the mixture blended for an additional three minutes to form the final blend. Tablets compressed therefrom had a breaking force of 2.0 kP (3.1 SCU) and disintegrated in 10 seconds in 5 ml of water.
  • Flash-melt tablets containing aripiprazole were prepared as follows:
  • the ingredients except for the magnesium stearate were blended in a commercial V-blender in geometric proportions for 5 minutes each until all were added.
  • the magnesium stearate was added and the mixture blended for an additional three minutes.
  • the blended formulation was compacted, and screened to form stable granules in accordance with the procedure of Example 1.
  • the intragranulation was placed in the blender and the Avicel® PH 200 and crospovidone added thereto and blended for five minutes. The magnesium stearate was then added and the mixture blended for an additional three minutes to form the final blend. Tablets compressed therefrom had a breaking force of 2.3 kP (3.5 SCU) and disintegrated in 10 seconds in 5 ml of water.
  • Flash-melt tablets can be prepared containing the antiviral medicament entecavir as follows:
  • the ingredients except for the magnesium stearate were blended in a commercial V-blender in geometric proportions for 5 minutes each until all were added.
  • the magnesium stearate was added and the mixture blended for an additional three minutes.
  • the blended formulation was compacted, and screened to form stable granules in accordance with the procedure of Example 1.
  • the intragranulation was placed in the blender and the Avicel® PH 200 and crospovidone added thereto and blended for five minutes. The magnesium stearate was then added and the mixture blended for an additional three minutes to form the final blend. Tablets compressed therefrom had a breaking force of 2.3 kP (3.5 SCU) and disintegrated in 10 seconds in 5 ml of water.
  • the percent w/w/ratios taught in this example can also be used to formulate a suitable formulation of the present invention comprising 0.1 mg of entecavir per unit dose.
  • Flash-melt tablets can be prepared containing the antibiotic medicament cefprozil as follows:
  • Flash-melt tablets can be prepared containing the antihypertensive medicament irbesartan as follows:
  • Flash-melt tablets can be prepared containing the quinolone antibiotic, des-Quinolone as follows:
  • Flash-melt tablets can be prepared containing the antibiotic gatifloxacin (Tequin®), as a taste masked co-precipitate (30% w/w active) to deliver 50 mg dose:
  • Aripiprazole 10.00 Xylitol, NF (Xylisorb 300) 21.15 Microcrystalline Cellulose, NF (Avicel PH 102) 10.0 Calcium Silicate, NF 36.5 Crospovidone, NF (XL-10) 3.0 Silicon Dioxide, NF (previously referred to as Amorphous Silica) 3.0 Croscarmellose Sodium, NF 2.0 Aspartame, NF 2.0 Flavor Creme de Vanilla 0.5 Tartaric Acid, NF 2 Acesulfame K (E.P) 2.0 Magnesium stearate NF 0.25 Total 92.40
  • the disintegration time for both prototypes in the mouth was less than 30 seconds.
  • the two prototypes show different dissolution rates in in-vitro dissolution tests using USP dissolution testing methods.
  • the goal of this study was to evaluate if these differences would affect in-vivo performance of the two prototypes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US12/558,813 2000-04-12 2009-09-14 Flashmelt oral dosage formulation Abandoned US20100016448A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/558,813 US20100016448A1 (en) 2000-04-12 2009-09-14 Flashmelt oral dosage formulation
US13/108,193 US8518421B2 (en) 2000-04-12 2011-05-16 Flashmelt oral dosage formulation
US13/938,706 US9358207B2 (en) 2000-04-12 2013-07-10 Flashmelt oral dosage formulation

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US54794800A 2000-04-12 2000-04-12
US58934000A 2000-06-07 2000-06-07
US09/973,226 US20020076437A1 (en) 2000-04-12 2001-10-09 Flashmelt oral dosage formulation
US10/920,851 US20050019398A1 (en) 2000-04-12 2004-08-18 Flashmelt oral dosage formulation
US10/979,556 US20070275059A1 (en) 2000-04-12 2004-11-02 Flashmelt oral dosage formulation
US5641008A 2008-03-27 2008-03-27
US12/558,813 US20100016448A1 (en) 2000-04-12 2009-09-14 Flashmelt oral dosage formulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US5641008A Continuation 2000-04-12 2008-03-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/108,193 Continuation US8518421B2 (en) 2000-04-12 2011-05-16 Flashmelt oral dosage formulation

Publications (1)

Publication Number Publication Date
US20100016448A1 true US20100016448A1 (en) 2010-01-21

Family

ID=24186805

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/558,813 Abandoned US20100016448A1 (en) 2000-04-12 2009-09-14 Flashmelt oral dosage formulation
US13/108,193 Expired - Fee Related US8518421B2 (en) 2000-04-12 2011-05-16 Flashmelt oral dosage formulation
US13/938,706 Expired - Fee Related US9358207B2 (en) 2000-04-12 2013-07-10 Flashmelt oral dosage formulation

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/108,193 Expired - Fee Related US8518421B2 (en) 2000-04-12 2011-05-16 Flashmelt oral dosage formulation
US13/938,706 Expired - Fee Related US9358207B2 (en) 2000-04-12 2013-07-10 Flashmelt oral dosage formulation

Country Status (43)

Country Link
US (3) US20100016448A1 (sl)
EP (2) EP1566174A3 (sl)
JP (1) JP3773763B2 (sl)
KR (1) KR100477293B1 (sl)
CN (1) CN100353933C (sl)
AR (1) AR024384A1 (sl)
AT (1) ATE328584T1 (sl)
AU (1) AU752214B2 (sl)
BG (1) BG65007B1 (sl)
BR (1) BR0003158A (sl)
CA (1) CA2311734C (sl)
CO (1) CO5190672A1 (sl)
CY (1) CY1105170T1 (sl)
CZ (1) CZ299145B6 (sl)
DE (1) DE60028536T2 (sl)
DK (1) DK1145711T3 (sl)
EE (1) EE04331B1 (sl)
EG (1) EG23943A (sl)
ES (1) ES2265836T3 (sl)
GE (1) GEP20022851B (sl)
HK (1) HK1039572B (sl)
HU (1) HU228864B1 (sl)
ID (1) ID29837A (sl)
IL (1) IL136901A (sl)
IN (1) IN188856B (sl)
LT (1) LT4896B (sl)
LV (1) LV12731B (sl)
MY (1) MY125766A (sl)
NO (1) NO330270B1 (sl)
NZ (1) NZ505302A (sl)
PE (1) PE20010298A1 (sl)
PL (1) PL200409B1 (sl)
PT (1) PT1145711E (sl)
RO (1) RO118563B1 (sl)
RU (1) RU2201216C2 (sl)
SG (2) SG108230A1 (sl)
SI (1) SI20511B (sl)
SK (1) SK286368B6 (sl)
TR (1) TR200001810A3 (sl)
TW (1) TWI262799B (sl)
UA (1) UA63993C2 (sl)
UY (1) UY26306A1 (sl)
ZA (1) ZA200003121B (sl)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090324729A1 (en) * 2008-05-02 2009-12-31 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
US20110217342A1 (en) * 2000-04-12 2011-09-08 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
WO2011148209A2 (en) 2010-05-28 2011-12-01 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság New use of diatomaceous earth in the pharmaceutical industry
CN102846543A (zh) * 2011-06-27 2013-01-02 上海中西制药有限公司 一种阿立哌唑药物制剂及其制备方法
US9891239B2 (en) 2007-02-23 2018-02-13 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
GB2617603A (en) * 2022-04-13 2023-10-18 Univ Brunel Compositions for preventing and treating infection

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020076437A1 (en) 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
PE20030445A1 (es) * 2001-09-25 2003-07-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
BR0117147A (pt) * 2001-10-09 2006-05-09 Bristol Myers Squibb Co preparado de dosagem oral de desintegração instantánea
US6610266B2 (en) * 2001-11-28 2003-08-26 Michael C. Withiam Calcium metasilicates and methods for making
US20050176793A1 (en) * 2001-12-10 2005-08-11 Reddy Reguri B. Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl)([1,1'-biphenyl)-4-yl)methyl)-1, 3-diazaspiro(4,4')non-1-en-4-one
KR20040098009A (ko) * 2002-03-06 2004-11-18 교와 핫꼬 고교 가부시끼가이샤 구강 내 속붕괴성 정제
AU2003238670A1 (en) * 2002-04-05 2003-10-27 Cadila Healthcare Limited Fast disintegrating oral dosage forms
MY131488A (en) * 2002-04-08 2007-08-30 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
ES2322953T3 (es) 2002-08-20 2009-07-02 Bristol-Myers Squibb Company Formulacion del complejo de aripiprazol y procedimiento.
CA2508811C (en) * 2002-12-11 2014-11-18 Bristol-Myers Squibb Company Process for preparing the antiviral agent [1s-(1.alpha., 3.alpha., 4.beta.)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one
JP3841804B2 (ja) * 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
US8349361B2 (en) 2003-10-15 2013-01-08 Fuji Chemical Industry Co., Ltd. Composition for rapid disintegrating tablet in oral cavity
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
JP3996626B2 (ja) * 2004-06-22 2007-10-24 塩野義製薬株式会社 口腔内速崩壊錠
KR20140065482A (ko) * 2005-03-24 2014-05-29 다이이찌 산쿄 가부시키가이샤 의약용 조성물
DE602006004694D1 (de) 2006-01-05 2009-02-26 Teva Pharma Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen
JP2008531738A (ja) * 2006-01-05 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド アリピプラゾールの乾燥製剤
EP1806130B1 (en) * 2006-01-09 2010-03-31 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising irbesartan
JP5535616B2 (ja) * 2006-03-31 2014-07-02 ルビコン リサーチ プライベート リミテッド 口腔内崩壊錠剤のための直接圧縮性複合材
WO2008125388A1 (en) * 2007-04-17 2008-10-23 Ratiopharm Gmbh Pharmaceutical compositions comprising irbesartan
JP2010526811A (ja) * 2007-05-08 2010-08-05 ハーキュリーズ・インコーポレーテッド 堅牢な迅速崩壊錠剤の処方
CN101322709B (zh) * 2007-06-12 2011-03-02 成都康弘药业集团股份有限公司 一种含有阿立哌唑的药物组合物及其制备方法
JP5296456B2 (ja) * 2008-08-26 2013-09-25 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
WO2010106936A1 (ja) * 2009-03-16 2010-09-23 ニプロ株式会社 口腔内崩壊錠
WO2010146551A2 (en) * 2009-06-16 2010-12-23 Ranbaxy Laboratories Limited Orally disintegrating compositions comprising antihypertensive agents
CA2773003A1 (en) 2009-09-15 2011-03-24 Ratiopharm Gmbh Orally disintegrating pharmaceutical dosage form containing aripiprazole
TR201000689A1 (tr) * 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Sefprozil içeren katı dozaj formlar.
CN102218040A (zh) * 2010-04-13 2011-10-19 齐鲁制药有限公司 一种阿立哌唑组合物微晶的口腔崩解片及其制备方法
EP2384742A1 (en) 2010-05-03 2011-11-09 The Jordanian Pharmaceutical Manufacturing Co. Pharmaceutical excipient, method for its preparation and use thereof
DE102010019416A1 (de) * 2010-05-04 2011-11-10 Stada Arzneimittel Ag Schmelztablette, umfassend ein Triptan oder ein atypisches Neuroleptikum
JP2012121850A (ja) * 2010-12-09 2012-06-28 Otsuka Pharmaceut Co Ltd アリピプラゾールの経口速溶性組成物
EP2685979B1 (en) 2011-03-18 2016-08-24 Alkermes Pharma Ireland Limited Injectable pharmaceutical compositions comprising a water-insoluble anti-psychotic, sorbitan laurate and polysorbate 20
MX2013010616A (es) * 2011-03-21 2014-08-18 Coloright Ltd Sistema de coloracion confeccionados.
CN102846564B (zh) * 2011-06-28 2013-10-09 南京亿华药业有限公司 一种头孢丙烯片及其制法
CN102357086A (zh) * 2011-11-01 2012-02-22 上海理工大学 一种头孢丙烯口腔崩解片
EP2797580A2 (en) * 2011-12-26 2014-11-05 Novartis AG Tablets and dry-coated agents
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
EP2827866B1 (en) 2012-03-19 2023-05-03 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
WO2013175508A2 (en) 2012-05-24 2013-11-28 Medreich Limited Stable pharmaceutical composition of aripiprazole
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
US20150224086A1 (en) * 2012-08-23 2015-08-13 Hetero Research Foundation Pharmaceutical Formulations of Rufinamide
WO2014080285A2 (en) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN102885790B (zh) * 2012-09-20 2013-12-25 中国人民解放军第三〇二医院 恩替卡韦分散片及其制备方法
AU2014260863A1 (en) 2013-04-30 2015-11-05 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
JP5714652B2 (ja) * 2013-06-13 2015-05-07 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
EP3065700A1 (en) 2013-11-07 2016-09-14 Synthon B.V. Orodispersible pharmaceutical compositions comprising aripiprazole
US9452131B2 (en) 2014-03-20 2016-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
JP5978335B2 (ja) * 2015-03-11 2016-08-24 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
KR20160139704A (ko) 2015-05-28 2016-12-07 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제, 및 이의 제조방법
JP2015172084A (ja) * 2015-07-06 2015-10-01 大塚製薬株式会社 アリピプラゾールの経口速溶性組成物
US9855227B2 (en) 2015-12-18 2018-01-02 The Procter & Gamble Company Quick dissolving diphenhydramine oral dosage form
TR201617675A2 (tr) 2016-12-02 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Ari̇pi̇prazole monohi̇drat formülasyonlarinin ağizda dağilan tablet formu
JP6572257B2 (ja) * 2017-05-16 2019-09-04 大塚製薬株式会社 アリピプラゾールの経口速溶性組成物
JP2017141299A (ja) * 2017-05-24 2017-08-17 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略
JP2018168185A (ja) * 2018-07-05 2018-11-01 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP2019203031A (ja) * 2019-09-06 2019-11-28 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
RU2732291C1 (ru) * 2020-02-13 2020-09-15 Открытое акционерное общество "Фармстандарт-Лексредства" (ОАО "Фармстандарт-Лексредства") Лекарственный препарат на основе травы алтея лекарственного для лечения простудных и острых респираторных заболеваний
CN115227661B (zh) * 2022-09-22 2022-12-13 北京惠之衡生物科技有限公司 一种利格列汀片及其制备方法

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966884A (en) * 1973-06-20 1976-06-29 Bureau De Recherches Geologiques Et Minieres Synthesis of wollastonite from natural materials without fusion
US3967974A (en) * 1969-03-12 1976-07-06 Reimbold & Strick Synthetic wollastonite and a process for its manufacture
US4254099A (en) * 1978-10-18 1981-03-03 Beiersdorf Aktiengesellschaft Pharmaceutical tablet composition
US4327080A (en) * 1981-07-13 1982-04-27 E. R. Squibb & Sons, Inc. Novel Bendroflumethiazide formulations and method
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5032552A (en) * 1988-07-04 1991-07-16 Tdk Corporation Biomedical material
US5393472A (en) * 1993-06-30 1995-02-28 Shaw; John D. Method of producing wollastonite & ceramic bodies containing wollastonite
US5424351A (en) * 1993-03-22 1995-06-13 Mizusawa Industrial Chemicals, Ltd. Antistatic agent for polyacetal resins
US5587172A (en) * 1993-09-10 1996-12-24 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US6103007A (en) * 1995-11-17 2000-08-15 Vrije Universiteit Brussel Inorganic resin compositions, their preparation and use thereof
US6133378A (en) * 1998-11-20 2000-10-17 Bridgestone/Firestone, Inc. EPDM-based roofing shingle compositions
US6287596B1 (en) * 1996-07-12 2001-09-11 Daiichi Pharmaceutical Co., Ltd. Quickly disintegratable compression-molded materials and process for producing the same
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
US6610266B2 (en) * 2001-11-28 2003-08-26 Michael C. Withiam Calcium metasilicates and methods for making
US20050019398A1 (en) * 2000-04-12 2005-01-27 Sanjeev Kotharl Flashmelt oral dosage formulation
US6858228B2 (en) * 1996-06-27 2005-02-22 Novartis Ag Solid oral dosage forms of valsartan

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622677A (en) * 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
DE2556561C2 (de) 1975-12-16 1983-04-14 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Herstellung von porösen Tabletten
DE2849494A1 (de) 1978-11-15 1980-05-29 Voss Gunter M Verfahren zur herstellung von arzneimittel-formlingen
ZA87279B (en) 1986-01-17 1987-09-30 Chugai Pharmaceutical Co Ltd Method for production of stable nicorandil preparation
EP0301006B1 (en) * 1986-04-01 1992-05-06 The Upjohn Company Methylprednisolone/sodium carboxymethyl starch tablet composition
SE8601624D0 (sv) 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4906478A (en) * 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
HU203041B (en) 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
IL110376A (en) * 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical preparations containing iftroban and methods for their preparation
AU7407194A (en) * 1993-08-03 1995-02-28 Warner-Lambert Company Pleasant tasting effervescent cold/allergy medications
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
TW430561B (en) * 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
ATE287218T1 (de) * 1996-02-29 2005-02-15 Fujisawa Pharmaceutical Co Schnellzerfallendes granulate von einem synthetischen süssstoff enthaltend kieselsäure und/oder siliciumdioxid
EP0918456A1 (en) * 1996-07-23 1999-06-02 Fmc Corporation Disintegrant composition for dispersible solids
JPH10114655A (ja) 1996-10-09 1998-05-06 Kyowa Hakko Kogyo Co Ltd 固形製剤
JPH10182436A (ja) 1996-10-31 1998-07-07 Takeda Chem Ind Ltd 固形医薬製剤
AUPO446397A0 (en) 1997-01-07 1997-01-30 Rees Equipment Pty Ltd Agricultural equipment direction control
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
TW527195B (en) * 1997-10-09 2003-04-11 Ssp Co Ltd Fast-soluble solid pharmaceutical combinations
JPH11152220A (ja) * 1997-11-19 1999-06-08 Daiichi Yakuhin Kogyo Kk 脂溶性薬物を含有した丸剤の製造方法
HUP0100469A2 (hu) * 1997-12-19 2001-08-28 Smithkline Beecham Corporation Eljárás harapással diszpergálható tabletták előállítására
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
EP1058538B9 (en) 1998-03-06 2013-01-02 Aptalis Pharma S.r.l. Fast disintegrating tablets
JP4027535B2 (ja) 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
CO5070643A1 (es) * 1998-05-27 2001-08-28 Merck & Co Inc Formulacion en tabletas comprimidas
JP2000119014A (ja) 1998-08-12 2000-04-25 Fuji Chem Ind Co Ltd 無晶形ケイ酸アルミン酸カルシウム複合酸化物及びその製造方法並びに制酸剤
JP2000086537A (ja) 1998-09-11 2000-03-28 Fuji Chem Ind Co Ltd 無機化合物糖類組成物、賦形剤、速崩壊性圧縮成型物及びその製造方法
GB9914936D0 (en) 1999-06-26 1999-08-25 Cerestar Holding Bv Directly compressible starch as enhancer of properties of excipients when used as binder and disintegrant for compression tablets
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
EP1410086A4 (en) 2001-06-29 2005-11-23 Xanoptix Inc CHARACTERIZED OPTIMIZATION AFTER TRAINING

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3967974A (en) * 1969-03-12 1976-07-06 Reimbold & Strick Synthetic wollastonite and a process for its manufacture
US3966884A (en) * 1973-06-20 1976-06-29 Bureau De Recherches Geologiques Et Minieres Synthesis of wollastonite from natural materials without fusion
US4254099A (en) * 1978-10-18 1981-03-03 Beiersdorf Aktiengesellschaft Pharmaceutical tablet composition
US4327080A (en) * 1981-07-13 1982-04-27 E. R. Squibb & Sons, Inc. Novel Bendroflumethiazide formulations and method
US5032552A (en) * 1988-07-04 1991-07-16 Tdk Corporation Biomedical material
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5424351A (en) * 1993-03-22 1995-06-13 Mizusawa Industrial Chemicals, Ltd. Antistatic agent for polyacetal resins
US5393472A (en) * 1993-06-30 1995-02-28 Shaw; John D. Method of producing wollastonite & ceramic bodies containing wollastonite
US5587172A (en) * 1993-09-10 1996-12-24 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US6103007A (en) * 1995-11-17 2000-08-15 Vrije Universiteit Brussel Inorganic resin compositions, their preparation and use thereof
US6858228B2 (en) * 1996-06-27 2005-02-22 Novartis Ag Solid oral dosage forms of valsartan
US6287596B1 (en) * 1996-07-12 2001-09-11 Daiichi Pharmaceutical Co., Ltd. Quickly disintegratable compression-molded materials and process for producing the same
US6133378A (en) * 1998-11-20 2000-10-17 Bridgestone/Firestone, Inc. EPDM-based roofing shingle compositions
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
US20050019398A1 (en) * 2000-04-12 2005-01-27 Sanjeev Kotharl Flashmelt oral dosage formulation
US20070275059A1 (en) * 2000-04-12 2007-11-29 Sanjeev Kothari Flashmelt oral dosage formulation
US6610266B2 (en) * 2001-11-28 2003-08-26 Michael C. Withiam Calcium metasilicates and methods for making

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110217342A1 (en) * 2000-04-12 2011-09-08 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
US8518421B2 (en) * 2000-04-12 2013-08-27 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
US9891239B2 (en) 2007-02-23 2018-02-13 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
US20090324729A1 (en) * 2008-05-02 2009-12-31 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
US10039718B2 (en) 2008-05-02 2018-08-07 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
WO2011148209A2 (en) 2010-05-28 2011-12-01 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság New use of diatomaceous earth in the pharmaceutical industry
CN102846543A (zh) * 2011-06-27 2013-01-02 上海中西制药有限公司 一种阿立哌唑药物制剂及其制备方法
GB2617603A (en) * 2022-04-13 2023-10-18 Univ Brunel Compositions for preventing and treating infection

Also Published As

Publication number Publication date
GEP20022851B (en) 2002-12-25
JP3773763B2 (ja) 2006-05-10
CA2311734A1 (en) 2001-10-12
RU2201216C2 (ru) 2003-03-27
EP1145711A1 (en) 2001-10-17
SG117445A1 (en) 2005-12-29
UY26306A1 (es) 2001-12-28
CN100353933C (zh) 2007-12-12
SI20511A (sl) 2001-10-31
NZ505302A (en) 2001-12-21
HUP0002316A2 (hu) 2002-11-28
CY1105170T1 (el) 2010-03-03
US9358207B2 (en) 2016-06-07
SG108230A1 (en) 2005-01-28
US20130296337A1 (en) 2013-11-07
ATE328584T1 (de) 2006-06-15
TR200001810A2 (tr) 2001-11-21
DE60028536T2 (de) 2007-05-16
IL136901A0 (en) 2001-06-14
CO5190672A1 (es) 2002-08-29
ZA200003121B (en) 2001-12-21
NO330270B1 (no) 2011-03-14
DE60028536D1 (de) 2006-07-20
JP2001302499A (ja) 2001-10-31
AR024384A1 (es) 2002-10-02
EG23943A (en) 2008-01-22
SK9732000A3 (en) 2001-11-06
PE20010298A1 (es) 2001-05-20
HK1039572B (zh) 2007-01-12
EE200000497A (et) 2001-12-17
LT2000064A (en) 2001-10-25
HK1039572A1 (en) 2002-05-03
LV12731B (en) 2002-03-20
ES2265836T3 (es) 2007-03-01
BG104693A (en) 2002-02-28
AU4373300A (en) 2001-10-18
PL200409B1 (pl) 2009-01-30
CN1317309A (zh) 2001-10-17
TWI262799B (en) 2006-10-01
EP1566174A2 (en) 2005-08-24
DK1145711T3 (da) 2006-10-02
PT1145711E (pt) 2006-11-30
US20110217342A1 (en) 2011-09-08
LT4896B (lt) 2002-02-25
IL136901A (en) 2008-03-20
HU0002316D0 (en) 2000-08-28
TR200001810A3 (tr) 2001-11-21
EP1145711B1 (en) 2006-06-07
ID29837A (id) 2001-10-18
PL341466A1 (en) 2001-10-22
EE04331B1 (et) 2004-08-16
BR0003158A (pt) 2001-12-18
SI20511B (sl) 2008-08-31
KR100477293B1 (ko) 2005-03-17
CZ20002391A3 (cs) 2001-11-14
CZ299145B6 (cs) 2008-04-30
EP1566174A3 (en) 2007-04-04
IN188856B (sl) 2002-11-16
RO118563B1 (ro) 2003-07-30
UA63993C2 (uk) 2004-02-16
KR20010096450A (ko) 2001-11-07
BG65007B1 (bg) 2006-12-29
AU752214B2 (en) 2002-09-12
NO20003196D0 (no) 2000-06-20
US8518421B2 (en) 2013-08-27
CA2311734C (en) 2011-03-08
SK286368B6 (sk) 2008-08-05
HUP0002316A3 (en) 2008-04-28
LV12731A (en) 2001-10-20
HU228864B1 (en) 2013-06-28
NO20003196L (no) 2001-10-15
MY125766A (en) 2006-08-30

Similar Documents

Publication Publication Date Title
US9358207B2 (en) Flashmelt oral dosage formulation
US20020076437A1 (en) Flashmelt oral dosage formulation
US20050019398A1 (en) Flashmelt oral dosage formulation
CA2462886C (en) Flashmelt oral dosage formulation
US20100016322A1 (en) Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
US20120028949A1 (en) Rapidly Disintegrating Tablet
US20050112196A1 (en) Rapidly disintegrating formulation
US5814339A (en) Film coated tablet of paracetamol and domperidone
US20110189274A1 (en) Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates
US9675551B2 (en) Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
EP3733166A1 (en) Cyclic orally disintegrating tablet
US20100272800A1 (en) Orally disintegrating olanzapine tablet
AU2002211557A1 (en) Flashmelt oral dosage formulation
ZA200402730B (en) Flashment oral dosage formulation.
MXPA00006125A (en) Flash-melt oral dosage formulation

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION